​
​

ZyVersa Therapeutics Stock (NASDAQ:ZVSA)

RevenueFinancialsChart
ZyVersa Therapeutics by TradingView

Previous Close

$1.23

52W Range

$1.04 - $42.35

50D Avg

$2.08

200D Avg

$4.54

Market Cap

$1.24M

Avg Vol (3M)

$1.22M

Beta

0.64

Div Yield

-

ZVSA Company Profile

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

7

IPO Date

Feb 11, 2022

Website

ZVSA Performance

ZVSA Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-107.75B$-13.01M$-7.70M
Net Income$-106.25B$-759.10M$-8.91M
EBITDA$-107.75B$-13.00M$-7.69M
Basic EPS$-108.97$-84.19$-0.44
Diluted EPS$-108.97$-84.19$-0.44

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
CNSPCNS Pharmaceuticals, Inc.
VECTVectivBio Holding AG
VIRIVirios Therapeutics, Inc.
AVROAVROBIO, Inc.
EFTReFFECTOR Therapeutics, Inc.
IMMXImmix Biopharma, Inc.
HEPAHepion Pharmaceuticals, Inc.
ZURAZura Bio Limited